• Lopinavir (ABT-378) Identified as MERS-CoV Inhibitor in FDA

  2026-06-08

  de Wilde et al. conducted a systematic screen of FDA-approved drugs and discovered that Lopinavir (ABT-378), among four small molecules, inhibits MERS-CoV replication at low micromolar concentrations in cell culture. This finding highlights the potential for repurposing HIV protease inhibitors for emerging coronavirus research and provides a framework for rapid-response antiviral studies.

• Batimastat (BB-94): Precision MMP Inhibition in Experimental

  2026-06-07

  Batimastat (BB-94) empowers researchers with robust, selective matrix metalloproteinase inhibition, enabling reproducible dissection of proteolytic signaling in cancer and neurobiology. The latest reference study reveals how targeted MMP blockade shapes BDNF processing at neuromuscular junctions, opening new avenues for synaptic and oncology research.

• ROS-Degradable Lipid Nanoparticles Enable Tumor-Selective mR

  2026-06-06

  This study introduces a combinatorial library of ROS-degradable lipid nanoparticles that enable selective mRNA delivery and expression in tumor cells. By exploiting the elevated intracellular ROS in cancer, the work demonstrates enhanced antitumor efficacy and opens avenues for precision mRNA therapeutics.

• Diclofenac: High-Purity Non-Selective COX Inhibitor for Rese

  2026-06-05

  Diclofenac is a non-selective cyclooxygenase inhibitor prized for its high purity and robust inhibition of prostaglandin synthesis. It is widely used in inflammation and pain signaling pathway research, including advanced intestinal organoid models. APExBIO supplies Diclofenac with validated quality for reproducible anti-inflammatory drug research.

• Asunaprevir (BMS-650032): Translational Leverage in HCV Rese

  2026-06-05

  This article provides translational researchers with mechanistic insights and actionable strategies for deploying Asunaprevir (BMS-650032) in hepatitis C virus (HCV) research. It explores the compound's broad inhibitory profile, delineates protocol nuances, contextualizes its impact within the evolving antiviral landscape, and bridges learnings from epigenetic oncology to inform future directions. APExBIO's Asunaprevir is positioned as a critical tool for those striving to advance HCV biology and therapeutic innovation.

• CAY10499: Applied Inhibitor of Human Hormone Sensitive Lipas

  2026-06-04

  CAY10499 stands out as a selective tool for dissecting lipase-driven metabolic and immunological mechanisms, especially in the context of tumor microenvironment research. This guide provides actionable workflows, optimization strategies, and troubleshooting insights for leveraging CAY10499 in advanced lipid metabolism and immunometabolism studies.

• ABT-199 (Venetoclax): Protocols & Innovation in Apoptosis As

  2026-06-04

  Harness the selectivity of ABT-199 (Venetoclax) to achieve precise Bcl-2 inhibition in hematologic malignancy and senescence research. This article details practical workflow optimizations, troubleshooting guidance, and the translational impact of senolytic strategies for advanced apoptosis assays.

• Sulfo-Cy3 Azide: Advancing Neurogenetic Mapping with Click C

  2026-06-03

  Discover how Sulfo-Cy3 azide, a next-generation bioconjugation reagent, is redefining fluorescent labeling in developmental neurobiology. This thought-leadership article bridges mechanistic insight with strategic guidance, contextualizing recent neurodevelopmental mapping breakthroughs and positioning Sulfo-Cy3 azide as an indispensable tool for translational researchers aiming for robust, reproducible imaging in complex biological systems.

• Ibrutinib (PCI-32765): Optimizing BTK Inhibition in B-Cell R

  2026-06-03

  Ibrutinib (PCI-32765) stands as a gold-standard BTK inhibitor for dissecting B-cell receptor signaling and modeling B-cell-driven diseases. This article translates the compound’s unique biochemistry into stepwise protocols, advanced use-cases, and evidence-backed troubleshooting strategies.

• SGI-1027 as a Precision Epigenetic Modulator in Cancer Resea

  2026-06-02

  Discover the unique role of SGI-1027, a potent DNA methyltransferase inhibitor, in reactivating tumor suppressor genes and advancing cancer epigenetics research. This article offers a deeper mechanistic and translational analysis supported by recent breakthrough studies.

• Branched Endosomal Disruptor Lipids Enhance mRNA and RNP Del

  2026-06-02

  This study introduces a new class of branched ionizable lipids (BEND) that significantly improve the delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complexes by promoting endosomal escape. These innovations advance the efficiency of hepatic gene editing and T cell engineering, with broad implications for non-viral nucleic acid therapeutics.

• HyperScript First-Strand cDNA Synthesis Kit: Advanced RNA to

  2026-06-01

  Leverage the HyperScript First-Strand cDNA Synthesis Kit for high-fidelity cDNA synthesis from even the most challenging RNA templates. Discover how its engineered reverse transcriptase outperforms conventional kits in gene expression studies—especially where secondary structure or low-abundance targets threaten assay sensitivity.

• Transmission Dynamics of Carbapenemase Genes in CREC in Guan

  2026-06-01

  This study systematically characterizes carbapenemase-encoding genes (CEGs) and their transmission dynamics in carbapenem-resistant Enterobacter cloacae (CREC) from eight teaching hospitals during the COVID-19 era. The findings highlight high rates of blaNDM-1 plasmid carriage, remarkable multidrug resistance, and efficient horizontal gene transfer, providing crucial insights for infection control and antimicrobial stewardship.

• ABT-199 (Venetoclax): Potent and Selective Bcl-2 Inhibitor

  2026-05-31

  ABT-199 (Venetoclax) is a highly selective, sub-nanomolar Bcl-2 inhibitor that induces apoptosis in BCL-2 dependent hematologic malignancies while sparing platelets. Its precision enables robust apoptosis assays and translational research in non-Hodgkin lymphoma and AML models.

• ABT-199 (Venetoclax): Applied Workflows in Apoptosis Assays

  2026-05-30

  ABT-199 (Venetoclax) offers unprecedented selectivity for Bcl-2, enabling precise apoptosis induction in hematologic and senescence research. This guide translates recent reference breakthroughs and validated protocols into actionable workflows, troubleshooting, and optimization strategies for advanced apoptosis modeling.

8125 records 11/542 page Previous Next First page 上5页 1112131415 下5页 Last page